Antibody therapeutics that bind CTLA4
There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Stimulation is achieved using antibodies that block binding of human CTLA4 to human B7 and diseases amenable to treatment by stimulation and augmentation of prolonging of immune responses include cancers of the prostate, kidney, colon, lung or breast; pathogenic infections; diseases associated with the CNS e.g. amyloidogenic diseases including Alzheimer's disease; and diseases with inflammatory or allergic components. Diseases amenable to treatment include graft versus host disease, host versus graft disease, allergy, autoimmune diseases and other inflammatory diseases.
1. An isolated fully human anti-CTLA4 antibody of an IgG class comprising a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 41; and a light chain variable domain comprising an amino acid sequence of SEQ ID NO. 42.
2. The fully human antibody of claim 1 , wherein the antibody has a heavy chain/light chain variable domain sequence of SEQ ID NO. 41/SEQ ID NO. 42 (called E8 herein).
3. An anti-CTLA4 fully human antibody fragment comprising a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 41; and a light chain variable domain comprising an amino acid sequence of SEQ ID NO. 42, wherein the fragment is a Fab fragment or a single chain antibody comprising a heavy chain variable domain and a light chain variable domain which are connected by a peptide linker.
4. The fully human antibody fragment of claim 3 , wherein the antibody fragment has a heavy chain/light chain variable domain sequence of SEQ ID NO. 41/SEQ ID NO. 42.
5. A method of treating cancer or another disease requiring stimulation of an immune response in a subject in need thereof, the method comprising administering an effective amount of the antibody of claim 1 , such that the cancer or other disease is treated.
6. The method of claim 5 , wherein the cancer is selected from the group consisting of bladder cancer, blood cancer, brain cancer, breast cancer, colon cancer, fibrosarcoma, lung cancer, ovarian cancer, prostate cancer, melanoma, lymphoma, mesothelioma, and plasmacytoma.
7. The method of claim 5 , wherein the antibody has a heavy chain/light chain variable domain sequence selected from the group consisting of SEQ ID NO. 41/SEQ ID NO. 42.
8. The method of claim 5 , wherein the cancer or another disease is selected from the group consisting of cancers of the prostate, kidney, colon, lung or breast, and pathogenic infections.